< Back to previous page
Researcher
Adrian Liston
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Systems biology, Molecular and cell biology, Immunology
Affiliations
- ADLI (Research group)
Responsible
From1 Jan 2017 → 31 Dec 2018 - Adaptive Immunology (Lab)
Member
From1 Jan 2012 → 31 Dec 2022
Infrastructure
1 - 1 of 1
- FACS Core facility : technology platform for next-generation cytometry. (Consortium coordinator)
Projects
1 - 10 of 49
See also Liston A for projects of Flanders Institute for Biotechnology.
Here below the projects of KU Leuven.
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Spectral flowcytometry (Cytek Aurora)From1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- Brain-resident lymphocytes: the role of Regulatory T cells in brainFrom1 Jan 2020 → 31 Dec 2020Funding: FWO research grant KAN
- Monogenic autoinflammatory disorders: streamlining the identification and validation of novel variants and exploring the phenotypic variability of disease.From1 Nov 2019 → 15 Nov 2019Funding: FWO junior postdoctoral fellowship
- The Role of Hepatocyte-Nuclear-Factor-1-A (HNF1A) in the Regulation of Glucose Homeostasis and Pancreatic Hormone SecretionFrom21 Mar 2019 → 9 Nov 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- In-depth investigation of autoinflammatory disordersFrom11 Mar 2019 → 15 Mar 2024Funding: FWO fellowships
- Functional DBF4 deficiency as novel DNA replication-associated inborn error of immunityFrom29 Jan 2019 → 2 Jun 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Evaluation of the clinical characteristics and molecular determinants of primary immunodeficiency in adults.From1 Oct 2018 → 30 Sep 2022Funding: FWO fellowships
- T regulatory cell expansion in the kidneyFrom1 Oct 2018 → 14 Oct 2019Funding: FWO fellowships
- Characterisation of the genetic and immunological factors controlling appropriate responses to infections in childrenFrom1 Oct 2018 → 30 Sep 2024Funding: BOF - projects, Fund Recuperation Fiscal Exemption
Publications
1 - 10 of 246
See also Liston A for publications of Flanders Institute for Biotechnology.
Here below the publications of KU Leuven.
- IP3R3 variants as novel form of hereditary disorders(2023)
- Functional DBF4 deficiency as novel DNA replication-associated inborn error of immunity(2023)
- Saying "no" to academic service(2023)Published in: Immunology and Cell BiologyISSN: 0818-9641Issue: 3Volume: 101Pages: 183 - 185
- DNA replication-associated inborn errors of immunity(2023)Published in: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYISSN: 0091-6749Issue: 2Volume: 151Pages: 345 - 360
- Immunology in Manchester(2023)Published in: Immunology and Cell BiologyISSN: 0818-9641Issue: 1Volume: 101Pages: 22 - 24
- Disrupted Ca2+ homeostasis and immunodeficiency in patients with functional IP3 receptor subtype 3 defects(2023)Published in: Cellular & Molecular ImmunologyISSN: 1672-7681Issue: 1Volume: 20Pages: 11 - 25
- RORγt-lineage APCs: The Aire apparent.(2022)Published in: Science immunologyISSN: 2470-9468Issue: 78Volume: 7Pages: eade9240
- UNRAVELING MOLECULAR DETERMINANTS IN ADULT-PRESENTING INBORN ERRORS OF IMMUNITY(2022)
- The Role of Hepatocyte-Nuclear-Factor-1-A (HNF1A) in the Regulation of Glucose Homeostasis and Pancreatic Hormone Secretion(2022)
- A Novel Homozygous Stop Mutation in IL23R Causes Mendelian Susceptibility to Mycobacterial Disease(2022)Published in: JOURNAL OF CLINICAL IMMUNOLOGYISSN: 0271-9142Issue: 8Volume: 42Pages: 1638 - 1652
Patents
1 - 6 of 6
- Glis3-manf gene therapy for preventing or treating diabetes
- Novel method and composition comprising il-2 and a tissue- or organ-specific targeting moiety
- Novel use and method comprising il-2 and a tissue- or organ-specific targeting moiety
- Novel method
- Novel method
- MCL-1 AS CRITICAL REGULATOR OF FOXP3+ REGULATORY T CELL SURVIVAL, AND USE THEREOF TO TREAT SEVERE IMMUNE DISORDERS